Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 56,171 shares, a decline of 15.1% from the February 12th total of 66,140 shares. Based on an average trading volume of 20,697 shares, the days-to-cover ratio is currently 2.7 days. Approximately 0.2% of the shares of the company are short sold. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 20,697 shares, the days-to-cover ratio is currently 2.7 days.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ DWTX opened at $3.06 on Monday. Dogwood Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.50. The firm has a market cap of $98.16 million, a P/E ratio of -0.12 and a beta of 1.90. The stock has a fifty day moving average price of $3.01 and a two-hundred day moving average price of $4.73.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Dogwood Therapeutics in a report on Friday, February 20th. Wall Street Zen lowered shares of Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $12.00.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. 9.05% of the stock is owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.